Nieuws en video's - Aandelen - Engels

Academy Sports + Outdoors Donates over $530K to St. Jude Children's Research Hospital® through Annual Holiday Partnership PR Newswire KATY, Texas, May 9, 2024 Total donation efforts have reached nearly $2.2 million over four years KATY, Texas , May 9, 2024 /PRNewswire/ -- Academy Sports + Outdoors ("Academy") ( Nasdaq: ASO ) today announced the donation of over $530,000 to St. Jude Children's Research Hospital® . The donation is a result of a collaboration between the two organizations to...

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- StepStone Group Inc. (Nasdaq: STEP) today announced that the Company will release its results for the fourth quarter and fiscal year ended March 31, 2024, after the market closes on Thursday, May 23, 2024. Webcast and Earnings Conference Call Management will host a webcast and conference call on Thursday, May 23, 2024, at 5:00 pm ET to discuss the Company’s results for the fourth quarter and fiscal year ended March 31, 2024. The webcast will be made...

ANN ARBOR, Mich., May 09, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that the spring production trials of the Company's new BAM-1 hybrid parental strains have concluded, exceeding all expectations for scale, performance and robustness. Kraig Labs reports that the spring production trials were an unabashed success. These trials proved that the Company's BAM-1 recombinant spider silk hybrids are ready for rapid...

Fathom Holdings to Participate in the 24th Annual B. Riley Securities Institutional Investor Conference PR Newswire CARY, N.C., May 9, 2024 CARY, N.C. , May 9, 2024 /PRNewswire/ -- Fathom Holdings Inc. (Nasdaq: FTHM) ("Fathom" or the "Company"), a national, technology-driven, end-to-end real estate services platform integrating residential brokerage, mortgage, title, insurance, and SaaS offerings for brokerages and agents, will participate in the 24 th Annual B. Riley Securities Institutional...

Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month; top line data for both trials now expected by end of third and fourth quarter of 2024, respectively Reported positive proof-of-concept for lonigutamab in thyroid eye disease patients and positive top-line Phase 2b/3 data for izokibep in psoriatic arthritis Cash, cash equivalents, and short-term marketable securities at March 31, 2024 of $678.5...

Mineros Reports First Quarter 2024 Financial and Operating Results PR Newswire MEDELLIN, Colombia, May 9, 2024 (all dollar amounts - other than per share amounts - are expressed in thousands of US dollars unless otherwise stated) MEDELLIN, Colombia , May 9, 2024 /PRNewswire/ - Mineros S.A. (TSX: MSA) (CB: MINEROS) (" Mineros " or the " Company ") today reported its financial and operating results for the three months ended March 31, 2024 . For further information, please see the Company's...

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire CAMBRIDGE, Mass., May 9, 2024 Dosed First Patient in the Single Ascending Dose Part 1 of the Phase 1 Clinical Trial of DA-1726 in Obesity, With Top-Line Data Readout Expected in the Third Quarter of 2024 Anticipate First Patient to be Dosed in the Multiple Ascending Dose Part 2 of the Phase 1 Clinical Trial of DA-1726 in the Third Quarter of 2024 Part 2 of the Phase 2a Trial of DA-1241...

Genel Energy PLC (GENL) Genel Energy PLC: Results of AGM 09-May-2024 / 13:00 GMT/BST 9 May 2024 Genel Energy plc Results of Annual General Meeting 9 May 2024 The Annual General Meeting of Genel Energy plc was held today, Thursday, 9 May 2024 and the results of the votes by shareholders are set out below. The number of ordinary shares of £0.10p each in the Company in issue at the date of the meeting was 279,402,863 and each share attracted one vote. The results were as follows: Resolutions For %...

ST. GALLEN, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company, today announced that Carsten Koerl, Chief Executive Officer, will participate in the J.P. Morgan 52nd Annual Global Technology, Media and Communications Conference at the Westin Boston Seaport District Hotel on Tuesday, May 21, 2024. Mr. Koerl will participate in a fireside chat at 8:10 a.m. EST that morning and that...

EQS-News: Volta Medical SAS / Key word(s): Miscellaneous Volta Medical Featured in Latest Consensus Statement from Leading International Cardiac Electrophysiology Societies on Atrial Fibrillation Ablation 09.05.2024 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Volta Medical Featured in Latest Consensus Statement from Leading International Cardiac Electrophysiology Societies on Atrial Fibrillation Ablation Published in the EP Europace Journal, the...

easyJet plc (EZJ) Holding(s) in Company 09-May-2024 / 13:00 GMT/BST TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B7KR2P84 Issuer Name EASYJET PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Bank of America Corporation City of registered office (if applicable) Country of registered office (if applicable) US 4. Details of the shareholder Full name...

CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences: RBC Capital Market Global Healthcare Conference Wednesday May 15 at 4:05 p.m. ET. (Fireside Chat) Link to register for the Fireside Chat can be found...

- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 - Received $50 million milestone following initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) - Clinical development milestones met and remain on track for the...

NEW YORK and KUALA LUMPUR, Malaysia, May 09, 2024 (GLOBE NEWSWIRE) -- Treasure Global Inc (NASDAQ: TGL) (“Treasure Global” or the “Company”), an innovative technology solutions provider, is thrilled to announce that its subsidiary, ZCITY, has secured a groundbreaking US$2 million marketing contract. This contract, honored by Satria Dunia Sdn Bhd, aims to promote prestige Korean beauty products through ZCITY’s advanced artificial intelligence marketing engine (“AI Marketing...

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-Risk NMIBC (IR-NMIBC) Final Results from CORE-001 Phase 2 Clinical Trial of Cretostimogene in Combination with Pembrolizumab in BCG-Unresponsive HR-NMIBC will be presented at ASCO 2024 Completed Oversubscribed and...

Mina Kim appointed Chief Executive Officer and to Board of Directors ACELYRIN Founder Shao-Lee Lin, M.D., Ph.D., steps down as Chief Executive Officer Shephard (Shep) Mpofu, M.D., MRCP, FRCP named Chief Medical Officer, Gil Labrucherie, the company’s Chief Financial Officer, additionally named Chief Business Officer, and Sanam Pangali named Chief Legal Officer and Head of People LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC . (Nasdaq: SLRN), a late-stage clinical biopharma...

Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatment Topline 96-week data from ORIGIN 2 trial expected in Q4 2024 Pivotal Phase 3 ORIGIN 3 trial estimated to complete enrollment for primary endpoint in Q3 2024 ; topline data expected in 1H 2025 Completed $287.5 million financing, further strengthening the Company’s balance sheet BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) --...

Bio-Equity Europe 2024 Asebio Investor Day 2024 RSC Hot Topics: Covalent Drug Discovery Foro Medcap BME 2024 MADRID, Spain and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in May. Oryzon will attend...

ROUYN-NORANDA, Quebec, May 09, 2024 (GLOBE NEWSWIRE) -- Abcourt Mines Inc. ("Abcourt" or the "Company") (TSX Venture : ABI) is pleased to confirm a second gold mineralized zone East of the Flordin deposit toward the Cartwright deposit 100% owned by Abcourt. Highlights • A petrographic study confirms the presence of gold grains in the pyrite. These gold grains would be associated with the second phase of pyrite crystallization. • Compilation work has shown that the gold is not only contained...

Presented top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), in April 2024 On track to deliver additional analyses from BEACON and AURORA in Q2 2024 Plan to present updated data from the phase 1b/2 study of DISC-0974 in anemia of myelofibrosis (MF), as well as initial single-ascending dose (SAD) data from the phase 1 study of DISC-3405 in healthy volunteers in Q2 2024 Continue to be well-capitalized, ending Q1 2024 with $343M in...